Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

143
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
143
Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

456
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
456

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Impact of immunosuppressive therapy on renal and patient survival in rapidly progressive secondary IgA nephropathy.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association·2026
Same author

Pivotal Clinical Trials in C3 Glomerulopathy: answers and remaining uncertainties.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association·2026
Same author

Pegcetacoplan Versus Iptacopan for the Treatment of Patients with C3 Glomerulopathy: Indirect Treatment Comparisons.

Advances in therapy·2026
Same author

Short versus long corticosteroid therapy for immune checkpoint inhibitors-induced acute tubulointerstitial nephritis.

Clinical kidney journal·2026
Same author

Chronic kidney disease progression in glomerular diseases: is hematuria a key risk factor?

Pediatric nephrology (Berlin, Germany)·2026
Same author

Extrarenal Disease in ANCA-Associated Vasculitis: Challenges and Evolving Therapeutic Strategies on behalf of the Immunonephrology Working Group (IWG) of the ERA.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association·2026

Related Experiment Video

Updated: Jul 9, 2025

Detection of MicroRNA Expression in the Kidneys of Immunoglobulin A Nephropathic Mice
05:39

Detection of MicroRNA Expression in the Kidneys of Immunoglobulin A Nephropathic Mice

Published on: July 8, 2020

1.9K

Targeting complement in IgA nephropathy.

Fernando Caravaca-Fontán1, Eduardo Gutiérrez2, Ángel M Sevillano2

  • 1Department of Nephrology, Instituto de Investigación Hospital 12 de Octubre (imas12), Madrid, Spain.

Clinical Kidney Journal
|December 6, 2023
PubMed
Summary
This summary is machine-generated.

Immunoglobulin A nephropathy (IgAN) involves complement system activation, impacting disease progression. Targeting complement pathways offers promising new treatments for this common kidney disease.

Keywords:
IgA nephropathyalternative pathwaylectin pathwaythrombotic microangiopathy

More Related Videos

Author Spotlight: Investigating the Potential of Chinese Herbal Medicinal Active Dioscin in Treating IgA Nephropathy
14:18

Author Spotlight: Investigating the Potential of Chinese Herbal Medicinal Active Dioscin in Treating IgA Nephropathy

Published on: October 13, 2023

1.8K
Analyses of Proteinuria, Renal Infiltration of Leukocytes, and Renal Deposition of Proteins in Lupus-prone MRL/lpr Mice
09:43

Analyses of Proteinuria, Renal Infiltration of Leukocytes, and Renal Deposition of Proteins in Lupus-prone MRL/lpr Mice

Published on: June 8, 2022

2.9K

Related Experiment Videos

Last Updated: Jul 9, 2025

Detection of MicroRNA Expression in the Kidneys of Immunoglobulin A Nephropathic Mice
05:39

Detection of MicroRNA Expression in the Kidneys of Immunoglobulin A Nephropathic Mice

Published on: July 8, 2020

1.9K
Author Spotlight: Investigating the Potential of Chinese Herbal Medicinal Active Dioscin in Treating IgA Nephropathy
14:18

Author Spotlight: Investigating the Potential of Chinese Herbal Medicinal Active Dioscin in Treating IgA Nephropathy

Published on: October 13, 2023

1.8K
Analyses of Proteinuria, Renal Infiltration of Leukocytes, and Renal Deposition of Proteins in Lupus-prone MRL/lpr Mice
09:43

Analyses of Proteinuria, Renal Infiltration of Leukocytes, and Renal Deposition of Proteins in Lupus-prone MRL/lpr Mice

Published on: June 8, 2022

2.9K

Area of Science:

  • Nephrology
  • Immunology
  • Complement System Biology

Background:

  • Immunoglobulin A nephropathy (IgAN) is the leading cause of primary glomerulonephritis globally.
  • Complement system activation, particularly the alternative pathway, plays a critical role in IgAN pathogenesis and progression.
  • Factor H-related proteins and lectin pathway activation are implicated in IgAN severity and complement dysregulation.

Purpose of the Study:

  • To comprehensively review the role of the complement system in IgAN pathogenesis.
  • To discuss emerging mechanisms of complement activation in IgAN.
  • To highlight the potential of complement inhibitors as novel therapeutic strategies for IgAN.

Main Methods:

  • Literature review of studies on complement activation in IgAN.
  • Analysis of the association between complement deposition (C3, C4d) and IgAN progression.
  • Review of ongoing clinical trials for complement-targeted therapies in IgAN.

Main Results:

  • Glomerular C3 deposition correlates with IgAN disease progression.
  • C4d deposition is linked to increased histologic activity and worse renal outcomes.
  • Thrombotic microangiopathy in IgAN indicates a poorer prognosis.

Conclusions:

  • Understanding complement's role in IgAN has led to the development of targeted therapies.
  • Several complement inhibitors targeting various components (Factor B, C3, C5, C5aR1) are under investigation.
  • Complement inhibition represents a promising therapeutic avenue for IgAN patients.